Review
The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease

https://doi.org/10.1016/j.kisu.2017.07.008Get rights and content
Under an Elsevier user license
open archive

The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector. Other deliverables include cataloging and maintaining up-to-date records to collate progress in renal research and development, inventorying the capacity of research and clinical networks, and describing methods to ensure novel drug development.

Keywords

drug re-purposing
personalized medicine
targeted treatment

Cited by (0)

21

Co-first authors.

22

GKHS Working Group Co-chairs.